Financial releases | Drupal

2024/09/26

Crossject announces its eligibility for France’s PEA-PME investment scheme

Read the release

2024/09/23

Crossject reports financial results and business highlights for the first six months of 2024

Read the release

2024/09/17

Crossject to report first-half 2024 financial results and host webcast on September 23, 2024

Read the release

2024/08/22

Crossject to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024

Read the release

2024/08/19

Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE® Epilepsy Rescue Treatment

Read the release

2024/07/18

Crossject achieves key ZEPIZURE® manufacturing milestone

Read the release

2024/07/15

Crossject to attend H.C. Wainwright 26th Annual Global Investment Conference

Read the release

2024/07/10

Crossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO® Epinephrine

Read the release

2024/06/26

Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence study

Read the release

2024/06/12

Crossject appoints Dan Chiche, MD as Chief Medical Officer North America

Read the release